Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine
Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine
About this item
Full title
Author / Creator
Feng, Weixu , Xiang, Yunru , Wu, Lianpeng , Chen, Zhuo , Li, Qingfeng , Chen, Jun , Guo, Yanru , Xia, Dandan , Chen, Na , Zhang, Lifang , Zhu, Shanli and Zhao, Kong‐Nan
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
SARS‐CoV‐2 has spread worldwide causing more than 400 million people with virus infections since early 2020. Currently, the existing vaccines targeting the spike glycoprotein (S protein) of SARS‐CoV‐2 are facing great challenge from the infection of SARS‐CoV‐2 virus and its multiple S protein variants. Thus, we need to develop a new g...
Alternative Titles
Full title
Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9169192
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9169192
Other Identifiers
ISSN
0887-8013,1098-2825
E-ISSN
1098-2825
DOI
10.1002/jcla.24479
